Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSA and Avatrombopag in Elderly Severe Aplastic Anemia
NCT05433922Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of avatrombopag in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Overall Response Rate at 24 weeks, Treatment-Emergent Adverse Events at 24 weeks and 1 more. Status: unknown.
02
Drugs
avatrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT05433922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05433922.